Activation of YAP1 by N6-Methyladenosine-Modified circCPSF6 Drives Malignancy in Hepatocellular Carcinoma.

Cancer Res

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang Province, Hangzhou, P.R. China.

Published: February 2022

AI Article Synopsis

  • The study explores the relationship between N6-methyladenosine (m6A) modifications and circular RNAs (circRNAs) in the context of hepatocellular carcinoma (HCC), identifying circCPSF6 as a key m6A-modified circRNA.
  • CircCPSF6 is found to be upregulated in HCC tissues and associated with poor patient survival, influencing cancer cell proliferation, motility, and metastasis through its interaction with the YAP1 protein.
  • The research reveals that circCPSF6 enhances the stability of YAP1 mRNA, promoting tumor aggressiveness, and suggests potential therapeutic targeting of this circRNA in HCC treatment.

Article Abstract

Unlabelled: Circular RNAs (circRNA) and N6-methyladenosine (m6A) modification are extensively involved in the progression of diverse tumors, including hepatocellular carcinoma (HCC). However, the cross-talk between circRNAs and m6A remains elusive in the pathogenesis of HCC. Here we investigated m6A-mediated regulation of circRNAs in HCC. m6A-related circRNAs were identified by integrating information from two published studies, revealing circular cleavage and polyadenylation specific factor 6 (circCPSF6) as a novel m6A-modified circRNA. circCPSF6 was dominated by ALKBH5-mediated demethylation, followed by the recognization and destabilization by YTHDF2. Meanwhile, circCPSF6 was upregulated in HCC specimens, and elevated circCPSF6 expression served as an independent prognostic factor for worse survival of patients with HCC. Loss-of-function assays demonstrated that circCPSF6 maintained cell proliferation and tumorigenicity and reinforced cell motility and tumor metastasis. circCPSF6 triggered expression of YAP1, further activating its downstream cascade. Mechanistically, circCPSF6 competitively bound PCBP2, blunting its binding to YAP1 mRNA, thereby sustaining the stability of YAP1. Functionally, removal of YAP1 reversed the effects of circCPSF6 in vitro and in vivo. Aberrant activation of the circCPSF6-YAP1 axis promoted HCC malignancy. These findings offer novel insights into the regulation of circRNAs by m6A modifications and the role of this epigenetic reprogramming in HCC.

Significance: This study advances the understanding of the interplay between m6A methylation and circRNAs in hepatocellular carcinoma, highlighting the potential of circCPSF6 as a therapeutic target.

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-21-1628DOI Listing

Publication Analysis

Top Keywords

hepatocellular carcinoma
12
circcpsf6
10
circrnas m6a
8
regulation circrnas
8
hcc
6
circrnas
5
activation yap1
4
yap1 n6-methyladenosine-modified
4
n6-methyladenosine-modified circcpsf6
4
circcpsf6 drives
4

Similar Publications

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. This study aimed to explore the role of hsa-miR-101-3p in HCC pathogenesis by identifying key genes and pathways. A comprehensive bioinformatics analysis revealed twelve hub genes (ETNK1, BICRA, IL1R1, KDM3A, ARID2, GSK3β, EZH2, NOTCH1, SMARCA4, FOS, CREB1, and CASP3) and highlighted their involvement in crucial oncogenic pathways, including PI3K/Akt, mTOR, MAPK, and TGF-β.

View Article and Find Full Text PDF

Objectives: While there is growing evidence that physical activity reduces the risk of hepatocellular carcinoma (HCC), the impact of occupational physical activity and sedentary behaviour remains unclear. This study aimed to investigate the associations between occupational physical activity and sedentary behaviour and HCC risk.

Design: Matched case-control study.

View Article and Find Full Text PDF

The 1-year survival rate of patients with unresectable hepatocellular carcinoma is less than 50%, which indicates a poor prognosis. Recently, the combination of atezolizumab and bevacizumab has improved the prognosis of patients with advanced hepatocellular carcinoma and has become the first-line treatment for unresectable hepatocellular carcinoma. However, there are few reports on conversion surgery after chemotherapy for unresectable hepatocellular carcinoma.

View Article and Find Full Text PDF

Drug therapy for hepatocellular carcinoma has made remarkable progress in recent years, and surgical resection of tumors that respond well to drug therapy has been performed in some cases. We report a case of hepatocellular carcinoma with hepatopulmonary metastases that was successfully treated with atezolizumab plus bevacizumab and surgically resected. The patient was a 56-year-old man who underwent a posterior segmentectomy and was diagnosed with hepatocellular carcinoma.

View Article and Find Full Text PDF

An 81-year-old man underwent a partial laparoscopic hepatectomy for tumors in the S7 segment of the liver and was diagnosed with moderately to poorly differentiated hepatocellular carcinoma(HCC). Two years and 10 months later, MRI identified a 10 mm tumor in the S8 segment of the liver, indicative of highly differentiated HCC. Colorectal endoscopy subsequently revealed a submucosal tumor in the transverse colon, with biopsy findings showing features similar to the previous HCC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!